Longer-term follow-up of patients with refractory and relapsed diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR) T cell therapy showed sustained responses in about half of the patients, suggesting that CAR-T therapy may be an effective option for this hard-to-treat non-Hodgkin's lymphoma, according to the ZUMA-1* and JULIET** trials presented at ASH 2017.
Combining aspirin with warfarin led to increased bleeding complications in patients with atrial fibrillation (AF) or venous thromboembolic disease (VTE) compared with warfarin alone, resulting in higher rates of major bleeding events and hospital admissions, according to data presented at ASH 2017.
Defibrotide treatment may be beneficial to adult patients with posthematopoietic stem cell transplantation (HSCT) hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), reports a new study presented at the concluded 59th American Society of Haematology Annual Meeting (ASH 2017).
Use of idelalisib plus ofatumumab in the frontline treatment of chronic lymphocytic leukaemia (CLL) is effective, yielding high overall response rate, although this is counterbalanced by significant toxicities, according to efficacy data from a phase II trial.
In the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), patients presenting BCR-ABL1 transcript levels ≤10 percent at 3 months are more likely to achieve major molecular response at 12 months with faster response rate compared with those who have transcript levels >10 percent, according to ≥12 months of follow-up data from the BFORE* trial.
Treatment with defibrotide is safe and effective for patients with veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following either allogeneic or autologous haematopoietic stem cell transplant (HSCT), according to the results of a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, Georgia.
Once-weekly subcutaneous administration of the bispecific humanized monoclonal antibody emicizumab successfully prevented or reduced bleeds with a favourable safety profile in paediatric patients with haemophilia A with inhibitors in the phase III HAVEN-2* trial, confirming the findings of a previous interim analysis.
Platelet count thresholds <20 x 109/L and <10 x 109/L are associated with major increased risk for both any and mucosal bleeding. Furthermore, platelet count, female sex and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) are risk factors for the risk of any bleeding, according to a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia.
In newly diagnosed, transplant-eligible multiple myeloma (MM) patients, induction therapy with cyclophosphamide-bortezomib-dexamethasone (CyBorD) delivers a comparable efficacy to bortezomib-dexamethasone (Vel-Dex), according to a new study presented at the recently concluded 59th American Society of Hematology Annual Meeting (ASH 2017).
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Consumption of whole almonds as snacks not only reduces low-density lipoprotein cholesterol (LDL-C) but also significantly improves endothelial function in adults with above-average risk of cardiovascular disease (CVD), according to the results of a trial.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.